Daniel O’Donnell

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO.

Phillips Edison-ARC Grocery Center REIT II, Inc. engages in investing in retail real estate properties. It focuses on the necessity-anchored neighborhood and community shopping centers. The company was founded on June 5, 2013 and is headquartered in Cincinnati. OH.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The company is based in Camberley, UK and was founded in 1981.

UCB Pharma SA discovers and develops biopharmaceutical products. It is a biopharmaceutical company focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is headquartered in Brussels, Belgium.

Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes.

Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

MyHealthTeam, Inc. operates social networks for communities of people facing autoimmune diseases and other chronic conditions. The firm provides social networks for autoimmune diseases including: multiple sclerosis, lupus, Crohn?s and ulcerative colitis, and rheumatoid arthritis. The company was founded by Eric Peacock and Mary Ray in 2010 and is headquartered in San Francisco, CA.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Twine Health, Inc. develops health coach software. Its platform offers shared decision making tools, which allow patients and clinicians to set goals and weigh management options to make informed decisions; self-tracking tools that allow patients to manage their conditions and build self-efficacy; dashboards for clinicians to identify patients; and integrated messaging tools. The company was founded by Frank Moss, John O. Moore and Scott Gilroy in 2013 and is headquartered in Cambridge, MA.

Stellular Bio, Inc. develops technology to produce independent human platelets from human induced pluripotent stem cells. The company was founded by Jonathan Thon, Joseph Italiano and Sven Karlsson in 2014 and is headquartered in Watertown, MA.

Phillips Edison Grocery Center REIT III, Inc. seeks to acquire and manage grocery-anchored neighborhood and community shopping centers with mix of national, regional, and local tenants selling necessity-based goods and services, and are anchored by a grocery provider in the region, with the specific grocery store demonstrating solid sales performance. The company was founded on April 15, 2016 and is headquartered in Cincinnati, OH.

Phillips Edison Grocery Center REIT II, Inc. provides real estate investment trust services. The company is headquartered in Lutherville-Timonium, MD.

LetsGetChecked, Inc. operates online platform which connects customers and diagnostic laboratories. It offers its diagnostics services for general health, sexual health, cancer screening and fertility and hormone check. The company was founded by Peter Foley in 2014 and is headquartered in Dun Laoghaire, Ireland.

Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts.

Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA.

Jasper Tx Corp. operates as a biotechnology company. It engages in the clinical development of novel therapies. The company was founded by Susan S. Prohaska and Judith Shizuru and is headquartered in Mountain View, CA.

Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA.

Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease.